A detailed history of Yeomans Consulting Group, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Yeomans Consulting Group, Inc. holds 255 shares of LLY stock, worth $235,546. This represents 0.09% of its overall portfolio holdings.

Number of Shares
255
Holding current value
$235,546
% of portfolio
0.09%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$724.87 - $909.04 $184,841 - $231,805
255 New
255 $231 Million
Q4 2023

Mar 14, 2024

BUY
$525.19 - $619.13 $460,066 - $542,357
876 New
876 $511 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $878B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Yeomans Consulting Group, Inc. Portfolio

Follow Yeomans Consulting Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yeomans Consulting Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Yeomans Consulting Group, Inc. with notifications on news.